Ms Kinga Malottki

Research Fellow

Public Health, Epidemiology and Biostatistics

Contact details

MRC Midland Hub for Trials Methodology Research
Public Health, Epidemiology and Biostatistics
Public Health Building
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

About

Kinga is a Research Fellow in the MRC Midland Hub for Trials Methodology Research. Her main research interests lie in the area of stratified medicine, particularly methods for evaluation and validation of predictive biomarkers.

Qualifications

  • Masters Degree in Economics, Warsaw School of Economics, Poland 2006
  • Masters Degree in International Relations Warsaw School of Economics, Poland 2006

Teaching

Research

  • Stratified Medicine
  • Trials Methodology
  • Systematic Reviews

Publications

Malottki K., Barton P., Tsourapas A., Uthman A., Liu Z., Routh K., Connock M., Jobanputra P., Moore D., Fry-Smith A., Chen Y-F. (2011), Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation., Health Technology Assessment, Vol. 15: No. 14.

Connock M., Tubeuf S., Malottki K., Uthman A., Round J., Bayliss S., Meads C., Moore D. (2010), Certolizumab pegol (CIMZIA®) for the treatment of Rheumatoid Arthritis., Health Technology Assessment., Vol. 14: Suppl. 2, 1-10.

Chen Y-F., Jowett S., Barton P., Malottki K., Hyde C., Gibbs S., et al (2009), Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation., Health Technology Assessment; Vol. 13: No.49.

Malottki K., Fry-Smith A., Moore D. (2008), Mapping the evidence base and use of neurostimulators. Report number 70, Unit of Public Health, Epidemiology and Biostatistics, University of Birmingham. ISBN: 0704427192 – 9780704427198

Back to top